Marina Biotech this week said that the US Patent and Trademark Office has issued a notice of allowance for three of the company's patent applications related to its delivery technologies.

The European Patent Office has also said it will grant the company a patent on a related technology, Marina said.

According to the company, the USPTO patent applications relate to the Smarticle amphoteric-based liposomal delivery vehicles Marina acquired from Novosom in 2010. The EPO application covers its DiLA2 amino acid-based liposomal delivery system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.